WallStSmart

Agnico Eagle Mines Limited (AEM)vsGilead Sciences Inc (GILD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Gilead Sciences Inc generates 147% more annual revenue ($29.44B vs $11.91B). AEM leads profitability with a 37.5% profit margin vs 28.9%. GILD appears more attractively valued with a PEG of 0.38. AEM earns a higher WallStSmart Score of 73/100 (B).

AEM

Strong Buy

73

out of 100

Grade: B

Growth: 8.0Profit: 9.0Value: 7.3Quality: 8.5
Piotroski: 6/9Altman Z: 2.83

GILD

Strong Buy

72

out of 100

Grade: B

Growth: 5.3Profit: 9.5Value: 10.0Quality: 5.5
Piotroski: 6/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AEMUndervalued (+47.7%)

Margin of Safety

+47.7%

Fair Value

$415.12

Current Price

$192.07

$223.05 discount

UndervaluedFair: $415.12Overvalued
GILDUndervalued (+53.9%)

Margin of Safety

+53.9%

Fair Value

$299.95

Current Price

$138.26

$161.69 discount

UndervaluedFair: $299.95Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AEM6 strengths · Avg: 9.5/10
Profit MarginProfitability
37.5%10/10

Keeps 38 of every $100 in revenue as profit

Operating MarginProfitability
64.7%10/10

Strong operational efficiency at 64.7%

Revenue GrowthGrowth
60.3%10/10

Revenue surging 60.3% year-over-year

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Market CapQuality
$89.62B9/10

Large-cap with strong market position

Free Cash FlowQuality
$1.30B8/10

Generating 1.3B in free cash flow

GILD6 strengths · Avg: 9.3/10
PEG RatioValuation
0.3810/10

Growing faster than its price suggests

Return on EquityProfitability
40.7%10/10

Every $100 of equity generates 41 in profit

Operating MarginProfitability
37.4%10/10

Strong operational efficiency at 37.4%

Market CapQuality
$171.45B9/10

Large-cap with strong market position

Profit MarginProfitability
28.9%9/10

Keeps 29 of every $100 in revenue as profit

EPS GrowthGrowth
23.4%8/10

Earnings expanding 23.4% YoY

Areas to Watch

AEM2 concerns · Avg: 3.0/10
EPS GrowthGrowth
2.0%4/10

2.0% earnings growth

PEG RatioValuation
28.152/10

Expensive relative to growth rate

GILD1 concerns · Avg: 4.0/10
Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Comparative Analysis Report

WallStSmart Research

Bull Case : AEM

The strongest argument for AEM centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 37.5% and operating margin at 64.7%. Revenue growth of 60.3% demonstrates continued momentum.

Bull Case : GILD

The strongest argument for GILD centers on PEG Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 28.9% and operating margin at 37.4%. PEG of 0.38 suggests the stock is reasonably priced for its growth.

Bear Case : AEM

The primary concerns for AEM are EPS Growth, PEG Ratio.

Bear Case : GILD

The primary concerns for GILD are Revenue Growth.

Key Dynamics to Monitor

AEM profiles as a growth stock while GILD is a value play — different risk/reward profiles.

AEM carries more volatility with a beta of 0.61 — expect wider price swings.

AEM is growing revenue faster at 60.3% — sustainability is the question.

GILD generates stronger free cash flow (3.1B), providing more financial flexibility.

Bottom Line

AEM scores higher overall (73/100 vs 72/100), backed by strong 37.5% margins and 60.3% revenue growth. GILD offers better value entry with a 53.9% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Agnico Eagle Mines Limited

BASIC MATERIALS · GOLD · USA

Agnico Eagle Mines Limited is engaged in the exploration, development and production of mineral properties in Canada, Sweden and Finland. The company is headquartered in Toronto, Canada.

Visit Website →

Gilead Sciences Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.

Want to dig deeper into these stocks?